Zevra Therapeutics, Inc. (NASDAQ:KMPH – Get Rating) was the recipient of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,370,000 shares, a decline of 5.5% from the January 31st total of 1,450,000 shares. Based on an average daily trading volume, of 210,400 shares, the short-interest ratio is currently 6.5 days. Approximately 4.4% of the company's stock are sold short.
Insider Activity
In other news, CEO Richard W. Pascoe purchased 9,500 shares of the company's stock in a transaction that occurred on Friday, January 13th. The shares were bought at an average price of $5.44 per share, for a total transaction of $51,680.00. Following the purchase, the chief executive officer now directly owns 19,973 shares in the company, valued at approximately $108,653.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.10% of the company's stock.
Get
Zevra Therapeutics alerts:
Institutional Investors Weigh In On Zevra Therapeutics
A number of large investors have recently made changes to their positions in KMPH. UBS Group AG bought a new position in shares of Zevra Therapeutics in the 2nd quarter worth approximately $26,000. Verition Fund Management LLC bought a new position in Zevra Therapeutics in the fourth quarter worth approximately $46,000. Invesco Ltd. purchased a new position in shares of Zevra Therapeutics during the 1st quarter worth $51,000. Kingsview Wealth Management LLC purchased a new stake in shares of Zevra Therapeutics in the 2nd quarter worth $54,000. Finally, HRT Financial LP bought a new position in Zevra Therapeutics in the 4th quarter worth $66,000. 19.39% of the stock is currently owned by institutional investors.
Zevra Therapeutics Stock Performance
Shares of KMPH opened at $5.81 on Wednesday. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.14. Zevra Therapeutics has a one year low of $4.00 and a one year high of $6.92. The business has a fifty day moving average of $5.34 and a 200 day moving average of $5.37.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Zevra Therapeutics in a research note on Thursday, November 17th. They issued an "overweight" rating and a $20.00 price target on the stock. Canaccord Genuity Group dropped their price target on shares of Zevra Therapeutics from $20.00 to $19.00 in a research note on Thursday, November 10th. Finally, StockNews.com raised Zevra Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 19th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.25.
About Zevra Therapeutics
(Get Rating)
KemPharm, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
Read More
- Get a free copy of the StockNews.com research report on Zevra Therapeutics (KMPH)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets "Powelled": S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023's Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
